Eventide Asset Management LLC Buys 44,425 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Eventide Asset Management LLC lifted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 19.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 272,954 shares of the biotechnology company’s stock after acquiring an additional 44,425 shares during the period. Eventide Asset Management LLC owned approximately 0.29% of Sarepta Therapeutics worth $34,089,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in SRPT. Riggs Asset Managment Co. Inc. increased its holdings in Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 75 shares in the last quarter. CIBC Asset Management Inc increased its holdings in Sarepta Therapeutics by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 86 shares in the last quarter. EP Wealth Advisors LLC increased its holdings in Sarepta Therapeutics by 2.1% during the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock worth $774,000 after purchasing an additional 103 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its holdings in Sarepta Therapeutics by 1.9% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock worth $1,000,000 after purchasing an additional 120 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. increased its holdings in Sarepta Therapeutics by 3.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock worth $557,000 after purchasing an additional 145 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Trading Up 5.7 %

Shares of SRPT stock opened at $137.94 on Friday. The firm has a 50 day moving average price of $122.16 and a two-hundred day moving average price of $131.43. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $13.18 billion, a PE ratio of 110.35 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 12-month low of $78.67 and a 12-month high of $173.25.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of research reports. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Raymond James reiterated an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Royal Bank of Canada restated an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 21st. Robert W. Baird decreased their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Finally, Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $152.00 to $167.00 in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $175.77.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.